Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF, Márquez-Malaver FJ, Carrillo E, Culebras MG, Morales R, Prats C, Vargas MT, Caballero T, Rodríguez-Arbolí E, Espigado I, Pérez-Simón JA. Falantes JF, et al. Among authors: marquez malaver fj. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):e1059-e1066. doi: 10.1016/j.clml.2022.08.012. Epub 2022 Aug 27. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36117041
A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.
Martín-Antonio B, Álvarez-Laderas I, Cardesa R, Márquez-Malaver F, Baez A, Carmona M, Falantes J, Suarez-Lledo M, Fernández-Avilés F, Martínez C, Rovira M, Espigado I, Urbano-Ispizua Á. Martín-Antonio B, et al. Bone Marrow Transplant. 2012 Sep;47(9):1206-11. doi: 10.1038/bmt.2011.253. Epub 2012 Jan 9. Bone Marrow Transplant. 2012. PMID: 22231458
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D. Perez-Simón JA, et al. Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065527 Free PMC article. Clinical Trial.
Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):144-52. doi: 10.1016/j.clml.2012.09.013. Epub 2012 Nov 6. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23137720
Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24220615
Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Calderón-Cabrera C, Márquez-Malaver FJ, de la Cruz-Vicente F, Falantes F, Carrillo E, Parody R, Montero I, González Campos J, Martino ML, Carmona M, Pérez-Simón JA, Espigado I. Calderón-Cabrera C, et al. Transplant Proc. 2013;45(10):3665-7. doi: 10.1016/j.transproceed.2013.11.007. Transplant Proc. 2013. PMID: 24314990
Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ, Calderón-Cabrera C, Márquez-Malaver FJ, Rodríguez N, Guijarro M, Espigado I, Núñez-Roldán A, Pérez-Simón JA, Aguilera I. Martínez-Bravo MJ, et al. Biol Blood Marrow Transplant. 2014 Sep;20(9):1356-62. doi: 10.1016/j.bbmt.2014.05.008. Epub 2014 May 17. Biol Blood Marrow Transplant. 2014. PMID: 24844856 Free article.
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Falantes J, et al. Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30. Leuk Res. 2015. PMID: 25487012 Clinical Trial.
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, Montero I, Parody R, Espigado I, Urbano-Ispizua A, Pérez-Simón JA. Falantes JF, et al. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25487600
30 results